Cost-Effectiveness Evidence to Inform Drug Reimbursement Decisions: Are Countries Converging in Process and Methods?
|
|
- Godfrey Nash
- 7 years ago
- Views:
Transcription
1 Cost-Effectiveness Evidence to Inform Drug Reimbursement Decisions: Are Countries Converging in Process and Methods? Mark Sculpher, PhD Professor of Health Economics Centre for Health Economics University of York, UK
2 Outline Overview of NICE process Overview of NICE methods Contrasts and similarities with other agencies internationally Scope for great harmonisation?
3 Outline Overview of NICE process Overview of NICE methods Contrasts and similarities with other agencies internationally Scope for great harmonisation?
4 The National Institute for Health and Clinical Excellence (NICE) Background Following election of Labour government 1997 Prolonged controversy about post code prescribing in the UK National Health Service Wish to de-politicize decisions about which technologies to cover in NHS Desire to use best available methods to address difficult questions
5 250 A short history of NICE Interventional Procedures QOF Quality standards Diag MD QS NHSE QOF 100 Clinical guidelines Public health PH IP Technologies CG TA /1 2001/2 2002/3 2003/4 2004/5 2005/6 2006/7 2007/8 2008/9 2009/ /11
6 NICE s activities Technology appraisal Pharmaceuticals Diagnostics (separate) Medical devices Guidelines Public health
7 The NICE process Overview Selection Assessment Appraisal
8 The NICE process Selection Not all licensed drugs selected NICE has key role in topic selection Criteria: Impact on costs Impact on health Innovative Recent predominance of cancer therapies
9 The NICE process Assessment multiple technology appraisals (MTAs) Longer review of several related technologies Scope sets up questions to be addressed Assessment period of about 6 months Undertaken by academic groups 3 key elements of the review: systematic review of clinical and economic evidence cost-effectiveness analysis critical review of sponsor (manufacturer) submission(s) Company submissions typically include model and systematic review All documents (and economic model) made available to consultees
10 The NICE process Assessment single technology appraisals (STAs) Change in 2006 in face of criticism about slowness Relates mainly to new pharmaceuticals Scope developed as for MTA Company provides all assessment clinical review, cost-effectiveness model Academic Evidence Review Group critically reviews submission
11 The NICE process Appraisal Patient organisation submissions Assessment reports Appraisal committee Manufacturer submissions Professional submissions Expert witnesses Patient witnesses
12 The NICE process Decisions Unconditional positive guidance Positive guidance conditional on particular patient characteristics Negative guidance Use recommended only in research Opportunity for appeal Decisions are reviewed in future
13 Outline Overview of NICE process Overview of NICE methods Contrasts and similarities with other agencies internationally Scope for great harmonisation?
14 NICE Reference Case Use of cost-effectiveness analysis NICE. Guide to the Methods of Technology Appraisal, 2008.
15 NICE Reference Case Use of QALYs to reflect health benefit NICE. Guide to the Methods of Technology Appraisal, 2008.
16 NICE Reference Case Use of QALYs to reflect health benefit Utility weights from public NICE. Guide to the Methods of Technology Appraisal, 2008.
17 NICE Reference Case Focus on health system costs alone NICE. Guide to the Methods of Technology Appraisal, 2008.
18 The NICE threshold Below a most plausible ICER of 20,000 per QALY gained, the decision to recommend the use of a technology is normally based on the costeffectiveness estimate and the acceptability of a technology as an effective use of NHS resources. When the estimated ICERs presented are less than 20,000 per QALY gained and the Committee judges that particular interventions should not be provided by the NHS, the recommendations will make specific reference to the Committee s view on the plausibility of the inputs to the economic modelling and/or the certainty around the estimated ICER. Above a most plausible ICER of 20,000 per QALY gained, judgements about the acceptability of the technology as an effective use of NHS resources will specifically take account of the following factors. - The degree of certainty around the ICER -. the change in HRQL has been inadequately captured - The innovative nature of the technology NICE. Guide to the Methods of Technology Appraisal. London: NICE, 2008.
19 Outline Overview of NICE process Overview of NICE methods Contrasts and similarities with other agencies internationally Scope for great harmonisation?
20 Process differences in other jurisdictions Drugs vs other technologies Full range of technologies Pharmaceuticals only NICE (England and Wales) HITAP (Thailand) IQWiG (Germany) HAS (France) SMC (Scotland) NCPE (Ireland) TLV (Sweden) Netherlands CDR (Canada) +++ Variation in whether decision making or not Some jurisdictions have separate organisations for drugs and other technologies
21 Process differences in other jurisdictions All drugs versus a selection Selection All drugs NICE (England and Wales) IQWiG (Germany) HAS (France) SMC (Scotland) TLV (Sweden) CDR Canada +++ Key distinction between organisations providing guidance and recommendations and those with mandatory reimbursement arrangements
22 Process differences in other jurisdictions Independent analysis versus manufacturer alone Independent analysis Manufacturer alone NICE MTA (England and Wales) IQWiG (Germany) NICE STA SMC (Scotland) NCPE (Ireland) TLV (Sweden) Netherlands CDR Canada +++
23 Other areas of difference in process Explicit setting of a scope Key part of all NICE activities One off decision versus periodic reviews NICE reviews every 2-4 years Level of detail provided about decisions All documentation and justification on NICE website Role of price in decisions Reference pricing systems (e.g. Netherlands) Free price setting (e.g. UK)
24 Methods differences between jurisdictions The emergence of some clustering? QALY based CEA - NICE - Canada - Australia - Sweden - Ireland Other economics - Germany - France - Various US health plans No (explicit) economics - US public sector
25 Methods differences between jurisdictions Variation remains within clusters - QALYs Issue CEA with QALYs General position Australia Generally Preferred Canada Optional Eng & Wales Required QoL weights MAUI generally Preferred Several options Described EQ-5D preferred Preferences Public Public Public Role of other methods CMA has a role CBA limited role CMA may have a role CMA, CEA and CBA all have a role Limited
26 Methods differences between jurisdictions Variation remains within clusters - perspective Payer Societal Both Not stated 13 (50%) 6 (23%) 6 (23%) 1 (4%) See Claxton K et al
27 Absence of clear rationale for selected perspective 50% of guidelines offer no rationale for their preferred perspective There is broad consensus nationally and internationally that the societal perspective is the most appropriate choice. (Netherlands) The perspective chosen should fit the needs of the target audience. (Canada) 27% (7/26) make reference to a budget constraint
28 Methods differences between jurisdictions Variation remains within clusters - comparator Most commonly used Existing, most effective or minimum practice Existing or most effective Justify Existing and no treatment Most common, least costly, no treatment Most common, least costly, no treatment, most effective Most common, least costly, most effective Most likely to be displaced Most efficient, most effective, do nothing All relevant comparators Most effective and no treatment Not clear/specific Tarn and Smith 2004; Sculpher and Drummond
29 Methods differences between jurisdictions Variation remains within clusters sensitivity analysis Need to state and justify Not stated/not specific Probabilistic sensitivity analysis (PSA) One-way, multi-way One-way, two-way Multi-way (of most important) One-way, multi-way and PSA One-way, multi-way and worst-best scenario One-way with tornado diagram Tarn and Smith 2004; Sculpher and Drummond 2006
30 More fundamental methodological differences IQWiG in Germany Economic analysis to support decisions of Ministry of Health and Sickness Funds Controversial methods recommendations by international panel Panel referred to constraints imposed by German law and IQWiG Little experience is using these methods in studies Caro et al, 2010; Sculpher and Claxton 2010
31 IQWiG methods Similar to NICEtype cluster Cost-effectiveness analysis Full range of comparators Use of sub-groups Some modelling permitted Recognised need for sumary measure of health Different to NICEtype cluster Decisions limited to specific disease areas Reluctant to have generic measure of outcome (especially the QALY) No general CE threshold used in decision making Role of modelling long term benefits unclear
32 More fundamental methodological differences HAS in France Decisions by HAS informed by Transparency Commission and Commission for Economic and Public Health Evaluation (CEESP) Reimbursement clinically driven SMR: benefit of drug ASMR: relative effectiveness versus comparators ASMR 1-3 companies set prices so decisions reflect implicit economic assessment Emerging role of CEESP to use economics but Post launch Part of broader HTA process
33 Scope for harmonisation? Various activities going on in Europe around HTA But many differences exist between jurisdictions in use of economic evaluation Process Methods major and minor Partly justifiable Scope for harmonisation in assessment Shared evidence (e.g. Reviews/meta analysis) Shared models Limited scope in decision making
34 References Sculpher MJ, Drummond MF. Analysis sans frontières: can we ever make economic evaluations generalisable across jurisdictions? Pharamacoeconomics. 2006;24(11): Tarn TY, Smith MD. Pharmacoeconomic guidelines around the world. ISPOR Connections 2004;10(4):5. Claxton K, Walker S, Palmer S, Sculpher M. Appropriate Perspectives for Health Care Decisions. CHE Research Paper 54 ( York: Centre for Health Economics, University of York; Caro J, Nord E, Siebert U, McGuire A, McGregor M, Henry D, et al. The efficiency frontier approach to economic evaluation of health-care interventions. Health Economics. 2010;DOI: /hec Sculpher M, Claxton K. Sins of Omission and Obfuscation: IQWiG s Guidelines on Economic Evaluation Methods. Health Economics. 2010;DOI: /hec.1629.
What is costeffectiveness?
...? series Second edition Health economics Supported by sanofi-aventis What is costeffectiveness? Ceri Phillips BSc(Econ) MSc(Econ) PhD Health Economist, Swansea University Cost-effectiveness analysis
More informationEndpoints and quality of life
Endpoints and quality of life PFS, OS, quality of life and medico-economic assessment in oncology Isabelle Durand-Zaleski, Jérôme Garnier, Mira Pavlovic, and participants of roundtable n 3 Pascal Bilbault,
More informationWhat are the HTA processes in the UK?
What is...? series New title The NHS and HTA Supported by sanofi-aventis What are the HTA processes in the UK? Michael Drummond PhD Professor of Health Economics, Centre for Health Economics, University
More informationWhat is health technology assessment?
...? series New title The NHS and HTA Supported by sanofi-aventis What is health technology assessment? Rebecca Taylor MSc Freelance Health Economist Rod Taylor PhD Associate Professor in Health Services
More informationThe fourth hurdle system. International HTA agencies. Australian PBAC. Difference between health technology regulatory body and HTA body
* This presentation is prepared by the author in one s personal capacity for the purpose of academic exchange and does not represent the views of his/her organisations on the topic discussed. Local Application
More informationA comparative analysis of the role and impact of Health Technology Assessment
FINAL REPORT Prepared For: EFPIA, PhRMA Medicines Australia and EuropaBio A comparative analysis of the role and impact of Health Technology Assessment Prepared By: Tim Wilsdon and Amy Serota 99 Bishopsgate
More informationCost Effectiveness, Reimbursement and Medical Devices. Colin Hopley M.Eng MBA MPH
Cost Effectiveness, Reimbursement and Medical Devices Colin Hopley M.Eng MBA MPH Agenda Health Care Environment Policy options - Health Technology Assessment (HTA) - Reimbursement Influence of innovation
More informationHEALTH ECONOMICS AND OUTCOMES RESEARCH SERVICES
HEALTH ECONOMICS AND OUTCOMES RESEARCH SERVICES Health Economics and Outcomes Research cannot operate in a silo. An optimal value proposition requires strong and robust HEOR statements. We develop the
More informationA new value-based approach to the pricing of branded medicines. Submission from the MS Society March 2011
A new value-based approach to the pricing of branded medicines About multiple sclerosis Submission from the MS Society March 2011 Multiple sclerosis (MS) is one of the most common disabling neurological
More informationA comparative analysis of the role and impact of Health Technology Assessment: 2013
Prepared For: PhRMA, Suite 300, 950 F Street, NW, Washington, DC 20004 EFPIA, Leopold Plaza Building, Rue du Trône 108, B-1050 Brussels (Belgium) A comparative analysis of the role and impact of Health
More informationNew Technology and Medical Decision Making: Ethics, Incentives, Regulation, and the Role of Health Policy
Panel Discussion on New Technology and Medical Decision Making: Ethics, Incentives, Regulation, and the Role of Health Policy with Speakers from the Conference and High-level Representatives from Health
More informationIncorporating Costs into Comparative Effectiveness Research
Research Insights Incorporating Costs into Comparative Effectiveness Research Summary Comparative-effectiveness research attempts to establish the relative health benefits of different drugs, medical devices,
More informationEvidence-based Health Policies for Medical Devices and Diagnostics in Asia. Outline of Presentation
Evidence-based Health Policies for Medical Devices and Diagnostics in Asia Prof Phua Kai Hong Chair, 2007-2008 Asia-Pacific Medical Devices & Diagnostics Council Lee Kuan Yew School of Public Policy The
More informationInternationale Standards des HTA? Jos Kleijnen Kleijnen Systematic Reviews Ltd
Internationale Standards des HTA? Jos Kleijnen Kleijnen Systematic Reviews Ltd Conflicts of Interest A Gutachten was commissioned by VFA we had full editorial freedom Kleijnen Systematic Reviews Ltd has
More informationW17: Understanding and modeling business decisions in market access and reimbursement using multi-criteria decision analysis techniques
W17: Understanding and modeling business decisions in market access and reimbursement using multi-criteria decision analysis techniques ISPOR 19 th International Meeting Montreal Tuesday June 3 rd 2014,
More informationMethods for the Estimation of the NICE Cost Effectiveness Threshold. Revised Report Following Referees Comments
Methods for the Estimation of the NICE Cost Effectiveness Threshold Revised Report Following Referees Comments Karl Claxton, 1,2 Steve Martin, 2 Marta Soares, 1 Nigel Rice, 1 Eldon Spackman, 1 Sebastian
More informationModerator: J van Loon,MSc Mapi. Advisor to the President, Head of International Affairs, HAS France
Comparing the challenges of comparative effectiveness Research in France, Italy and the Netherlands Current Situation and Perspectives Issue Panelists: F. Meyer, MD Advisor to President, France E. Xoxi,
More informationHTA Position Paper. The International Network of Agencies for Health Technology Assessment (INAHTA) defines HTA as:
HTA Position Paper The Global Medical Technology Alliance (GMTA) represents medical technology associations whose members supply over 85 percent of the medical devices and diagnostics purchased annually
More informationACD 3.0 - To Evaluate the Risk Assessment System
TOCILIZUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS REPORT BY THE DECISION SUPPORT UNIT Stephen Palmer, Mark Sculpher Centre for Health Economics, University of York 6 May 2010 1 CONTENTS 1. SYNOPSIS
More informationUNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator(s)
UNIVERSITY OF BIRMINGHAM AND UNIVERSITY OF YORK HEALTH ECONOMICS CONSORTIUM (NICE EXTERNAL CONTRACTOR) Health economic report on piloted indicator(s) Pilot QOF indicator: The percentage of patients 79
More informationIssue date: October 2009. Guide to the single technology appraisal process
Issue date: October 2009 Guide to the single technology appraisal process Guide to the single technology appraisal process Issued: October 2009 This document is one of a series describing the processes
More information1. Comparative effectiveness of alemtuzumab
Cost-effectiveness of alemtuzumab (Lemtrada ) for the treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features The NCPE has issued
More informationCancer Drug Reimbursement within the Context of Clinical Trials. (Draft for consultation purposes) Version 8.0
Cancer Drug Reimbursement within the Context of Clinical Trials (Draft for consultation purposes) Version 8.0 May 17, 2013 Introduction Clinical and cost-effectiveness factors have led most public payers
More informationKey principles for the improved conduct of health technology assessments for resource allocation decisions
International Journal of Technology Assessment in Health Care, 24:3 (2008), 244 258. Copyright c 2008 Cambridge University Press. Printed in the U.S.A. doi:10.1017/s0266462308080343 Key principles for
More informationA competency framework for all prescribers updated draft for consultation
A competency framework for all prescribers updated draft for consultation Consultation closes 15 April 2016 Contents 1 Introduction... 3 2 Uses of the framework... 4 3 Scope of the competency framework...
More informationHow To Understand The Cost Effectiveness Of Bortezomib
DOI: 1.331/hta13suppl1/5 Health Technology Assessment 29; Vol. 13: Suppl. 1 Bortezomib for the treatment of multiple myeloma patients C Green, J Bryant,* A Takeda, K Cooper, A Clegg, A Smith and M Stephens
More informationCost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis
Cost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness
More informationValue-based pricing for pharmaceuticals: Its role, specification and prospects in a newly devolved NHS. CHE Research Paper 60
Value-based pricing for pharmaceuticals: Its role, specification and prospects in a newly devolved NHS CHE Research Paper 60 Value-based pricing for pharmaceuticals: Its role, specification and prospects
More informationImproving Quality and Efficiency in Health Care through Comparative Effectiveness Analyses: An International Perspective
Improving Quality and Efficiency in Health Care through Comparative Effectiveness Analyses: An International Perspective by Gerry Fairbrother, Ph.D.; Ellen O Brien, Ph.D.; Rosina Pradhananga, M.P.H.; Kalipso
More informationCost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis.
Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis. March 2013 1. Pirfenidone is indicated in adults for the treatment of mild to moderate Idiopathic Pulmonary
More informationWhat is a QALY? What is...? series. Second edition. Health economics. Supported by sanofi-aventis
...? series Supported by sanofi-aventis Second edition Health economics What is a QALY? Ceri Phillips BSc(Econ) MSc(Econ) PhD Professor of Health Economics, Swansea University A quality-adjusted life-year
More informationW7: Statistical Challenges in HTA
W7: Statistical Challenges in HTA Chair: Claire Watkins, Statistical Science Director, AstraZeneca Speakers: Keith Abrams, Professor of Medical Statistics, University of Leicester Nicholas Latimer, Research
More informationCost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis
Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness of teriflunomide
More informationHealth Economics. The Basics. Pat Berrigan Fall 2015
Health Economics The Basics Pat Berrigan Fall 2015 1 Topics 1) What is heath economics and why do we do it; 2) Types of health economic analyses; 3) Cost-effectiveness analysis; 4) The incremental cost-effectiveness
More informationHEALTH CARE DELIVERY IN BRITAIN AND GERMANY: TOWARDS CONVERGENCE?
HEALTH CARE DELIVERY IN BRITAIN AND GERMANY: TOWARDS CONVERGENCE? Background: Two different health care systems Generally speaking, the British and the German health care systems differ not only with respect
More informationThe decision making process and the application of value judgments. Francis Ruiz Senior Adviser (Health Economics) NICE International April 2014
The decision making process and the application of value judgments Francis Ruiz Senior Adviser (Health Economics) NICE International April 2014 NICE 2014 Process matters! The ideal situation? Principles
More informationAn introduction to value-based healthcare in Europe
An article from The Economist Intelligence Unit An introduction to value-based healthcare in Europe European governments, like those in other parts of the world, are feeling the strain on their health
More informationChander Sehgal, MD, MBA Director, Common Drug Review (CDR) Taipei, Taiwan July 23 26, 2012
Chander Sehgal, MD, MBA Director, Common Drug Review (CDR) Taipei, Taiwan July 23 26, 2012 CANADIAN PERSPECTIVE Common Drug review: A *pan-canadian process CANADA: 33 M people; area 10 M km 2 DIVERSITY!
More informationFluoride and Dental Health in Europe
Fluoride and Dental Health in Europe Dental Health in Europe - A Problem for Disadvataged Groups Report of an EU-funded Conference A conference of dental and public health experts drawn from every Member
More informationTOCILIZUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
TOCILIZUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS REPORT BY THE DECISION SUPPORT UNIT 2 nd September 2011 Jon Minton, Paul Tappenden, Jonathan Tosh School of Health and Related Research, University
More informationNational Disability Authority Resource Allocation Feasibility Study Final Report January 2013
National Disability Authority Resource Allocation Feasibility Study January 2013 The National Disability Authority (NDA) has commissioned and funded this evaluation. Responsibility for the evaluation (including
More informationHealth Economics South West Webinar Series 12 October 2015 Rebecca Worboys presenting Nicola Bowtell Facilitating Dominic Gallagher Facilitating
Health Economics South West Webinar Series 12 October 2015 Rebecca Worboys presenting Nicola Bowtell Facilitating Dominic Gallagher Facilitating Rebecca Worboys Health Economist Housekeeping rules Please
More informationBREVE 6 HEALTH BENEFITS PLANS IN OECD COUNTRIES
BREVE 6 HEALTH BENEFITS PLANS IN OECD COUNTRIES Presentation by Valérie Paris. May 2014 A series on policies and methods based on presentations for experts. Prepared by CRITERIA, a knowledge network on
More informationCase study 4 Revlimid and Multiple Myeloma*... Payer approval ...
* Summary Need Revlimid brings benefits to myeloma patients, by slowing disease progressing and lengthening patients lives. Myeloma affects 1.3 in every 10,000 people. In the UK just under 5,000 people
More informationPharmacoeconomic Analyses and Oncology Pharmacy: Optimizing Multiple Myeloma Value for Patients and Plans
Pharmacoeconomic Analyses and Oncology Pharmacy: Optimizing Multiple Myeloma Value for Patients and Plans C. Daniel Mullins, PhD Professor Pharmaceutical Health Services Research Department University
More informationNational Centre for Pharmacoeconomics. Guidelines for Inclusion of Drug Costs in Pharmacoeconomic Evaluations
National Centre for Pharmacoeconomics Guidelines for Inclusion of Drug Costs in Pharmacoeconomic Evaluations Version 1.10 Please Note: This document may be updated periodically, therefore please refer
More informationAdalimumab for the treatment of psoriasis
DOI: 10.3310/hta13suppl2/07 Health Technology Assessment 2009; Vol. 13: Suppl. 2 Adalimumab for the treatment of psoriasis D Turner, J Picot,* K Cooper and E Loveman Southampton Health Technology Assessments
More informationTable 1 Overview of evidence-based decision-making processes for pharmaceutical coverage in 36 countries
Table 1 Overview evidence-based -making processes for pharmaceutical in 36 countries Austria Belgium Bulgaria Croatia Cyprus HVB INAI CPR (oh) HZZO CH (oh) PO R PO,IP NA NA HEK at HVB (level) INAI staff,
More informationAppendix 3 INDIVIDUAL PATIENT DRUG TREATMENT. POLICY AND PROCESS FOR DECISION MAKING September 2007
Appendix 3 INDIVIDUAL PATIENT DRUG TREATMENT POLICY AND PROCESS FOR DECISION MAKING September 2007 Approved by Board: 6 th September 2007 Date Implemented: 1 st October 2007 Review Date: September 2008
More informationBriefing on Personnel Leasing in the European Union
Annex 13 Briefing on Personnel Leasing in the European Union 1. Economic significance In the EU (15 Member States; there are not yet any figures of the 10 new Member States) there are about 1,4 million
More informationReport and Commentary on the Eurodoc Statement of Standards in the Assessment, Expectations and Outcomes of Doctoral Programmes in Europe
Report and Commentary on the Eurodoc Statement of Standards in the Assessment, Expectations and Outcomes of Doctoral Programmes in Europe Edited by Tim Brown Supervision and Training Workgroup Coordinator
More informationT H E STATE OF LATE PAYMENT. www.marketinvoice.com // @marketinvoice
T H E STATE OF PAYMENT www.marketinvoice.com // @marketinvoice THE PAYMENT REPORT JANUARY 02 CONTENTS 04 KEY FACTS 05 PAYMENT OVER TIME 06 BLUE CHIPS VS SMES 07 BLUECHIPS & FTSE 350 08 SME 09 BIG TECH
More informationChoices in Methods for Economic Evaluation
Choices in Methods for Economic Evaluation A METHODOLOGICAL GUIDE Choices in Methods for Economic Evaluation October 2012 Department of Economics and Public Health Assessment 1 Choices in Methods for Economic
More informationWales Patient Access Scheme: Process Guidance
Wales Patient Access Scheme: Process Guidance July 2012 (Updated September 2014) This guidance document has been prepared by the Patient Access Scheme Wales Group, with support from the All Wales Therapeutics
More informationInternational comparisons of obesity prevalence
International comparisons of obesity prevalence June 2009 International Comparisons of Obesity Prevalence Executive Summary Obesity prevalence among adults and children has been increasing in most developed
More informationFinal Report. Assessing the Challenges of Applying Standard Methods of Economic Evaluation to Public Health Interventions
Final Report Assessing the Challenges of Applying Standard Methods of Economic Evaluation to Public Health Interventions 1 Assessing the Challenges of Applying Standard Methods of Economic Evaluation to
More informationApixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation
Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation ERRATUM This report was commissioned by the NIHR HTA Programme as project number 11/49 This document
More informationSummary 1. Comparative-effectiveness
Cost-effectiveness of Delta-9-tetrahydrocannabinol/cannabidiol (Sativex ) as add-on treatment, for symptom improvement in patients with moderate to severe spasticity due to MS who have not responded adequately
More informationJSA in Germany with BfArM/PEI and G-BA
JSA in Germany with BfArM/PEI and G-BA 16 th DGRA Annual Congress Bonn, 8 May 2014 Thomas Mueller Head of Pharmaceuticals Department Federal Joint Committee (GBA) Seite 3 2014 Thomas Müller AMNOG in brief
More informationValue Based Pricing (VBP) in Swedish Health Care
1 Value Based Pricing (VBP) in Swedish Health Care Ulf Persson IHE, The Swedish Institute for Health Economics & Institute of Economic Research, School of Economics and Management, Lund University, Sweden
More informationSPEAKER BIOGRAPHICAL INFORMATION
SPEAKER BIOGRAPHICAL INFORMATION Madeleine R. Valera MD, MScIH (Heidelberg) Dr. Valera is a senior health care service professional with over 20 years of professional expertise in Health Financing and
More informationHow does the NHS buy HIV Drugs?
The April 2011 announcement of changes to HIV drugs purchasing arrangements in London highlighted the direct impact of National Health Service (NHS) drugs procurement budgets and processes on individual
More informationhttp://www.mig.tu-berlin.de
Post-licensing evaluation of new medicines 25 20 15 10 A valuable tool to foster true pharmaceutical innovations? An international perspective Dr. Annette Zentner MD, MPH Dept. Health Care Management Rationale
More informationRisk-sharing Agreements: Country Experiences and Challenges
Risk-sharing Agreements: Country Experiences and Challenges 101/2014 INSEAD Healthcare Management Initiative www.insead.edu/hmi hmi@insead.edu Written by Ridhima Aggarwal, The Salmon and Rameau Research
More informationHealth Insurance. Perception & Reality. Salman Rawaf MD PhD FRCP FFPH. Professor of Public Health Erbil Iraq 2-4 Feb 2011 s.rawaf@imperial.ac.
WHO Collaborating Centre Imperial College London Health Insurance Perception & Reality Salman Rawaf MD PhD FRCP FFPH Professor of Public Health Erbil Iraq 2-4 Feb 2011 s.rawaf@imperial.ac.uk Content Health
More informationHEALTH SYSTEM. Introduction. The. jurisdictions and we. Health Protection. Health Improvement. Health Services. Academic Public
FUNCTIONS OF THE LOCAL PUBLIC HEALTH SYSTEM Introduction This document sets out the local PH function in England. It was originally drafted by a working group led by Maggie Rae, FPH Local Board Member
More informationMarket Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform
Market Access for Medical Technology & Pharmaceutical Companies An Organizational Priority in Times of Economic Austerity and Reform By Joakim Steen Mikkelsen, Managing Healthcare Counselor, Embassy of
More informationPrinciples for application of international reference pricing systems
Principles for application of international reference pricing systems International reference pricing (IRP) is a widely used element of price regulation in the vast majority of EU and EFTA countries. While
More informationQuality and critical appraisal of clinical practice guidelines a relevant topic for health care?
Quality and critical appraisal of clinical practice guidelines a relevant topic for health care? Françoise Cluzeau, PhD St George s Hospital Medical School, London on behalf of the AGREE Collaboration
More informationSOCIAL VALUE JUDGEMENTS
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SOCIAL VALUE JUDGEMENTS Principles for the development of NICE guidance Second edition 1 Contents Contents...2 Preface...3 1 Introduction...4 1.1 Background...4
More informationThe NCPE has issued a recommendation regarding the use of pertuzumab for this indication. The NCPE does not recommend reimbursement of pertuzumab.
Cost Effectiveness of Pertuzumab (Perjeta ) in Combination with Trastuzumab and Docetaxel in Adults with HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer Who Have Not Received Previous
More informationJ Clin Oncol 28:3234-3238. 2010 by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 20 JULY 10 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Comparison of Anticancer Drug Coverage Decisions in the United States and United Kingdom: Does the Evidence Support
More informationNational Institute for Health and Clinical Excellence
House of Commons Health Committee National Institute for Health and Clinical Excellence First Report of Session 2007 08 Volume I Report, together with formal minutes Ordered by The House of Commons to
More informationHTA NETWORK MULTIANNUAL WORK PROGRAMME 2016-2020
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Healthcare systems, medical products and innovation Medical products: quality, safety, innovation Brussels, 20 May 2016 HTA NETWORK MULTIANNUAL
More informationProcess for advising on the feasibility of implementing a patient access scheme
Process for advising on the feasibility of implementing a patient access scheme INTERIM September 2009 Patient Access Schemes Liaison Unit at NICE P001_PASLU_Process_Guide_V1.3 Page 1 of 21 Contents (to
More informationLevel 5 Diploma in Managing the Supply Chain (QCF) Qualification Specification
Level 5 Diploma in Managing the Supply Chain (QCF) Qualification Specification Created: May 2012 Version: 1.0 Accreditation Number: 600/5605/8 Qualification Start Date: 1 st June 2012 Qualification Last
More informationDisinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review
Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review Bonny Parkinson, Catherine Sermet, Fiona Clement, Steffan Crausaz, Brian Godman, Sarah Garner, Moni Choudhury,
More informationHow Medical Devices Are Reimbursed in Europe
How Medical Devices Are Reimbursed in Europe Rational decision making in reimbursement decisions to provide optimal care at acceptable cost!? Mattias Kyhlstedt, CEO Synergus AB 1 European Reimbursement:
More informationMedical Technologies Evaluation Programme Methods guide
Issue date: April 2011 Medical Technologies Evaluation Programme Methods guide National Institute for Health and Clinical Excellence MidCity Place 71 High Holborn London WC1V 6NA www.nice.org.uk National
More informationPUBLIC RECORD. Record of Determinations Fitness to Practise Panel. Dates 07 May 2015-08 May 2015. Medical Practitioner. Dr John Stanley Partington
PUBLIC RECORD Dates 07 May 2015-08 May 2015 Name of Medical Practitioner Dr John Stanley Partington Primary medical qualification MB BS 1987 University of Newcastle upon Tyne GMC reference number 3184336
More informationHTA Uncovered. The introduction of economic evaluations have hitherto not influenced ASMR ratings claimed by manufacturers in France
Issue No. 8 June 0 HTA Uncovered The introduction of economic evaluations have hitherto not influenced ASMR ratings claimed by manufacturers in France Since the publication of the 008 Social Security Financing
More informationCARDIFF UNIVERSITY PROFESSIONAL DOCTORATES REVISED CORE PRINCIPLES
1 Core principles CARDIFF UNIVERSITY PROFESSIONAL DOCTORATES REVISED CORE PRINCIPLES The following are core principles which help to define the nature of Professional Doctorates awarded by Cardiff University..1
More informationSecond International Comparative Study of Mortality Tables for Pension Fund Retirees
Second International Comparative Study of Mortality Tables for Pension Fund Retirees T.Z.Sithole (Kingston University), S.Haberman (Cass Business School, City University London) and R.J.Verrall (Cass Business
More informationTherapeutic strategies for the treatment of pain
First EFIC Symposium - Societal Impact of Pain Brussells 4-5 May 2010 Therapeutic strategies for the treatment of pain Paolo D. Siviero Economic Strategy and Pharmaceutical Policy Department Office for
More informationCost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip
Cost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip Replacement or Total Knee Replacement National Centre
More informationRituximab for the treatment of relapsed or refractory stage III or IV follicular non-hodgkin s lymphoma
DOI: 10.3310/hta13suppl2/06 Health Technology Assessment 2009; Vol. 13: Suppl. 2 Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-hodgkin s lymphoma A Boland, A Bagust,
More informationThe UK Quality Code for Higher Education: A brief guide
UK Quality Code for Higher Education The UK Quality Code for Higher Education: A brief guide The UK Quality Code for Higher Education: A brief guide The UK Quality Code for Higher Education (the Quality
More informationThe new EU Clinical Trials Regulation How NHS research and patients will benefit
the voice of the NHS in Europe Briefing September 2014 Issue 19 The new EU Clinical Trials Regulation How NHS research and patients will benefit Who should read this briefing? This briefing will be of
More informationSkills performance measures Delivering our ambition for skills in Wales
Skills performance measures Delivering our ambition for skills in Wales Skills performance measures Delivering our ambition for skills in Wales Audience All bodies concerned with post-19 education and
More informationINDIVIDUAL FUNDING REQUEST POLICY for NHS Great Yarmouth and Waveney and NHS Norfolk
INDIVIDUAL FUNDING REQUEST POLICY for NHS Great Yarmouth and Waveney and NHS Norfolk This policy covers: Individual Funding Requests for Medicines(IFR-M) and Individual Funding Requests for Procedures
More informationIntercultural Communication in Business (6) Multicultural teams and Framework for Intercultural Management
Intercultural Communication in Business (6) Multicultural teams and Framework for Intercultural Management Group Effectiveness Multi Cultural Groups Single Cultural Groups Highly Average Highly Ineffective
More informationThe Burden of Rheumatoid
The Burden of Rheumatoid Arthritis (RA) and Patient Access to Treatment by prof. Bengt Jönsson, DR. Gisela Kobelt and PROF. Josef Smolen summary of key findings Table of contents Introduction Introduction
More informationAugust 2012. Authors: Ben Kearns, Roberta Ara, Allan Wailoo School of Health and Related Research, University of Sheffield
A REVIEW OF THE USE OF STATISTICAL REGRESSION MODELS TO INFORM COST EFFECTIVENESS ANALYSES WITHIN THE NICE TECHNOLOGY APPRAISALS PROGRAMME REPORT BY THE DECISION SUPPORT UNIT August 2012 Authors: Ben Kearns,
More informationMeasuring Health System Performance Lecture 11 Benchmarking and public reporting of provider performance
Measuring Health System Performance Lecture 11 Benchmarking and public reporting of provider performance Reinhard Busse, Prof. Dr. med. MPH Department of Health Care Management Berlin University of Technology/
More informationRegulatory Impact Assessment (RIA) Date: /08/15 Type of measure: Subordinate Legislation Lead department or agency: Department for Social Development
Title: Charities accounts: independent examination and audit thresholds Regulatory Impact Assessment (RIA) Date: /08/15 Type of measure: Subordinate Legislation Lead department or agency: Department for
More informationObjectives. P&T Committee. P&T Committee Structure. Utilization of P&T Committees
Objectives Discuss overview of forum purpose. Drug Information used in the Managed Care Pharmacy P&T Decision Making Process: Current Practice and Insights Diana Brixner, RPh, PhD Professor and Chair,
More informationCLINICAL EXCELLENCE AWARDS. Academy of Medical Royal Colleges submission to the Review Body on Doctors and Dentists Remuneration
CLINICAL EXCELLENCE AWARDS Academy of Medical Royal Colleges submission to the Review Body on Doctors and Dentists Remuneration Introduction The Academy of Medical Royal Colleges (the Academy) welcomes
More informationNWL CSU IFR Team CLINICAL COMMISSIONING GROUP BRIEFING. UPDATE OF THE PPwT POLICY ON IN-VITRO FERTILISATION (IVF)
NWL CSU IFR Team CLINICAL COMMISSIONING GROUP BRIEFING UPDATE OF THE PPwT POLICY ON IN-VITRO FERTILISATION (IVF) NWL CSU- PPwT Version 3 update- IVF Page 1 of 9 1. INTRODUCTION The NHS NWL policy on access
More informationESRC International Co-Investigators Policy: Guidance on the inclusion of International Co-Investigators ESRC proposals
ESRC International Co-Investigators Policy: Guidance on the inclusion of International Co-Investigators ESRC proposals Background Many major issues requiring research evidence (eg the global economic crisis,
More informationAttributing the costs of health and social care Research and Development (AcoRD)
Attributing the costs of health and social care Research and Development (AcoRD) Page 1 of 8 Contents Contents. 2 Purpose.. 3 Background. 3 Basic Principles.. 4 Commercial Contract Studies.. 4 Non-commercial
More information